Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [2][82]. Core Insights - The animal health industry has shown significant growth in vaccine issuance, with most vaccine varieties experiencing year-on-year increases in the first three quarters of the year. Key vaccines such as porcine epidemic diarrhea, porcine circovirus, and others have demonstrated strong performance [9][12]. - The Veterinary Product Index (VPI) has shown a continued upward trend in October, indicating a recovery in raw material prices for veterinary drugs after a period of decline [3][58]. - The report highlights that the industry is gradually emerging from a low point, with a focus on undervalued companies that exhibit both elasticity and certainty in their performance [71][72]. Summary by Sections Vaccine Issuance - Cumulative data from January to September shows that most vaccine varieties have experienced significant year-on-year growth, particularly in porcine vaccines, with increases of 9.1% for foot-and-mouth disease vaccine, 29.5% for porcine circovirus vaccine, and 60.2% for brucellosis vaccine [9][12]. - The report notes that the growth in vaccine issuance is driven by multiple factors, including farming profitability, increased slaughter rates, and the introduction of new products [13][14]. Raw Material Prices - As of October 22, the VPI stands at 69.29, reflecting a 0.1% increase from the end of September and a 6.4% increase year-on-year. This marks a recovery after three consecutive months of decline [58][61]. - The report indicates that the prices of most veterinary raw materials have improved, with significant increases noted for products like Tylosin and Amoxicillin [59][61]. Investment Recommendations - The report suggests focusing on companies that have shown resilience and innovation, such as Reap Bio, Kexin Bio, and others, as they are expected to perform well in the recovering market [71][73]. - It emphasizes that the competitive landscape is shifting, with larger companies likely to outperform smaller ones, leading to potential consolidation in the industry [72][73].

Core Viewpoint - The A-share market is experiencing a surge in flu-related stocks, driven by rising flu activity in southern provinces and the emergence of the H3N2 strain, which has led to increased investor interest in pharmaceutical companies [1][2] Company Performance - **Jinshi Yiyao**: Increased by 13.44%, with a total market value of 4.644 billion [2] - **Guangji Pharmaceutical**: Rose by 9.97%, total market value of 2.448 billion [2] - **Te Yi Pharmaceutical**: Gained 8.78%, market value of 5.209 billion [2] - **Hualan Biological Engineering**: Up by 8.59%, with a market value of 12.9 billion [2] - **Lingkang Pharmaceutical**: Increased by 7.01%, market value of 4.291 billion [2] - **Hengdi Pharmaceutical**: Rose by 6.60%, market value of 5.466 billion [2] - **Innotec**: Increased by 5.37%, market value of 4.459 billion [2] - **Weikang Pharmaceutical**: Up by 4.76%, market value of 3.471 billion [2] - **Yirui Biological**: Increased by 4.67%, market value of 4.359 billion [2] Market Trends - The China CDC reported a slow increase in respiratory disease cases nationwide, with flu activity rising in southern provinces and remaining low in northern regions [1] - Experts suggest that the flu season may arrive earlier this year, with a potential increase in infection rates due to lower immunity against the H3N2 strain [1]

Meeting Overview - The second extraordinary general meeting of shareholders was held on October 10, 2025, at the company's conference room in Shandong [2] - The meeting was convened by the board of directors and chaired by Chairman Peng Xin, utilizing a combination of on-site and online voting methods [2][3] Attendance - All 9 current directors and 3 current supervisors attended the meeting, along with the board secretary and other senior management [3] Resolutions Passed - The following resolutions were approved: - Cancellation of the supervisory board and amendment of the Articles of Association [4] - Amendments to various governance documents, including: - Shareholders' meeting rules [5] - Board meeting rules [5] - Independent director work system [5] - External guarantee management system [5] - External investment management system [5] - Management measures for the use of raised funds [5] - Related party transaction management system [5] - The first resolution was a special resolution, requiring more than two-thirds of the voting rights held by attending shareholders for approval [5] Legal Verification - The meeting was witnessed by Beijing Tongshang Law Firm, with lawyers confirming that the meeting's procedures complied with relevant laws and regulations [6]

北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2025 年第二次临时股东大会的 法律意见书 二〇二五年十月 中国北京市建国门外大街 1 号国贸写字楼 2 座 12-14 层 100004 12-14th Floor, China World Office 2, No.1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2025 年第二次临时股东大会的法律意见书 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对本次股东大 会依法进行了见证，并对有关文件和事实进行了必要的核查和验证，现出具法律意见如 下： 一、关于本次股东大会的召集、召开程序 本次股东大会系由公司董事会召集。2025 年 9 月 19 日，公司第十一届董事会第九 次（临时）会议审议通过了《关于召开公司 2025 年第二次临时 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-051 山东鲁抗医药股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 10 月 10 日 (二)股东大会召开的地点：山东鲁抗医药股份有限公司高新园区 A1115 会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,610 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 249,755,048 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 27.7916 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，董事长彭欣先生主持。本次会议以现场投票及 网络投票相结合的方式进行表决，会议的召集、召开和表决方 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公司董事会将根据上述批复文件和相关法律法规要求以及公司股东大会的授权，在规定期限内办理本次 向特定对象发行股票相关事宜，并及时履行信息披露义务。敬请广大投资者注意投资风险。 山东鲁抗医药股份有限公司（以下简称"公司"）近日收到中国证券监督管理委员会（以下简称"中国证 监会"）出具的《关于同意山东鲁抗医药股份有限公司向特定对象发行股票注册的批复》（证监许可 [2025]2158号），主要内容如下： 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送上海证券交易所的申报文件和发行方案实施。 三、本批复自同意注册之日起12个月内有效。 四、自同意注册之日起至本次发行结束前，你公司如发生重大事项，应及时报告上海证券交易所并按有 关规定处理。 证券代码:600789 证券简称:鲁抗医药 公告编号:2025-050 山东鲁抗医药股份有限公司 关于向特定对象发行股票申请获得中国证监会同意注册批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 特此公告。 山 ...

Core Insights - Vitamin B12, also known as cobalamin, is essential for human health, playing a critical role in nerve function and preventing pernicious anemia. It is used in the treatment of various diseases such as cerebral hemorrhage, Alzheimer's disease, and acute myelitis. The market demand for Vitamin B12 supplements is increasing due to rising health awareness among consumers. The market size of the cobalamin industry in China is projected to reach 1.4 billion yuan in 2024, representing a year-on-year growth of 6% [1][10]. Industry Overview - Cobalamin, or Vitamin B12, is the only vitamin that contains a metal element. It is a red crystalline powder that is water-soluble and plays multiple indispensable roles in the human body, including maintaining a healthy nervous system and promoting red blood cell production [3][10]. - The primary sources of Vitamin B12 are animal products, with some plant sources like soybeans containing lower amounts. The vitamin is crucial for protein and amino acid synthesis, especially in infants [3]. Market Dynamics - China is a major supplier of Vitamin B12 globally, with significant export volumes. The export quantity of unblended Vitamin B12 and its derivatives is expected to grow from 355.08 tons in 2020 to 498.08 tons by 2024 [10]. - The competition in the cobalamin market is intensifying due to limited market size and high domestic production capacity. Major players include Hebei Huaron, Yuxing Bio, Ningxia Jinyi, and Jiutian Pharmaceutical [10][11]. Production Methods - The cobalamin industry primarily utilizes microbial fermentation methods for production, as chemical synthesis is complex and costly. The fermentation process mainly involves anaerobic fermentation using Propionibacterium and aerobic fermentation using Pseudomonas [8]. Industry Trends - The cobalamin industry is expected to see continuous technological innovation, focusing on refining extraction methods and enhancing product stability. The use of biotechnological advancements will likely lead to higher activity and lower impurity levels in cobalamin products [12]. - There is a trend towards high-end and diversified product offerings to meet varying consumer needs, including specialized products for anemia treatment and a wider range of dosage forms [13]. - The industry is moving towards environmentally sustainable practices, including green sourcing of raw materials and energy-efficient extraction processes [14].

Group 1 - The core viewpoint of the report indicates that the majority of vaccine varieties have experienced significant year-on-year growth from January to August, particularly in the pet vaccine sector, with domestic rabies vaccine and cat trivalent vaccine increasing by 16.8% and 78.9% respectively [1][2] - In the pig vaccine category, the economic product circular vaccine and mandatory vaccines such as pseudorabies and swine fever vaccines have shown rapid growth, attributed to sustained breeding prosperity and increased pig inventory [1][3] - The VPI index for veterinary raw materials has rebounded by approximately 2.1% by the end of September, following a three-month decline, driven by supply-side tightening and large downstream orders [4][5] Group 2 - The report highlights that the growth in vaccine issuance is supported by multiple factors including breeding prosperity, inventory growth, disease prevalence, and the introduction of new products [3][6] - The increase in prices for veterinary raw materials is primarily due to supply-side changes and improved market competition, with specific products like florfenicol benefiting from a more favorable supply environment [5][6] - The industry is gradually emerging from a downturn, with a focus on undervalued companies that exhibit both elasticity and certainty, suggesting a positive outlook for the sector [7]

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting the industry index to outperform the benchmark index by over 5% in the next 3-6 months [81]. Core Insights - The animal health industry is gradually emerging from a low point, with a focus on undervalued companies that exhibit both elasticity and certainty. The report highlights that the ongoing internal competition has led to a market cleanup, with a recovery in the prices of veterinary raw materials and significant improvements in the year-on-year issuance of various vaccine types [70][71]. - The report emphasizes the importance of innovation in companies that have performed well, whether through product innovation, marketing strategies, or capital operations, which is reflected in their financial performance [70][71]. Summary by Sections Vaccine Issuance - In the first eight months of the year, most vaccine types showed significant year-on-year growth, particularly in swine vaccines such as foot-and-mouth disease vaccine (+11.0%), porcine reproductive and respiratory syndrome vaccine (+38.1%), and others. The report notes that the cat tri-vaccine saw a remarkable increase of +78.9% [10][11][9]. - The report indicates that the growth in vaccine issuance is driven by multiple factors, including the continued prosperity of farming, increased livestock inventory, disease outbreaks, and the introduction of new products [11][10]. Veterinary Raw Materials - As of September, the Veterinary Price Index (VPI) was reported at 69.22, reflecting a month-on-month increase of 2.0% and a year-on-year increase of 8.7%. This marks the first month-on-month increase after three consecutive months of decline [56][59]. - The report highlights that the price of various veterinary raw materials has improved, with significant increases in the prices of products like tiamulin and florfenicol, driven by supply constraints and increased demand [56][59]. Investment Recommendations - The report suggests focusing on companies that are undervalued yet possess strong growth potential, such as RuiPu Biological, KeQian Biological, and others. It notes that the competitive landscape is shifting, with larger companies outperforming smaller ones, indicating a potential for market consolidation in the future [70][71].

Group 1 - The core point of the article is that LuKang Pharmaceutical (600789) has had its application for a non-public stock issuance approved and registered as effective [1] - The company plans to issue up to 270 million shares to no more than 35 specific investors, including Hualu Group [1] - The expected fundraising amount from this issuance is 1.2 billion yuan [1] Group 2 - The underwriting institution for this issuance is China International Capital Corporation [1]